AKT1 and neoplasm: Targeting metabolic reprogramming via the EGFR/AKT and mevalonate pathways or modifying cholesterol and fatty acid synthesis, in conjunction with leveraging oxidative stress-induced DNA damage in tumor cells, presents alternative strategies to hinder the progression of GBM [144].